Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)

NCT ID: NCT05983471

Last Updated: 2025-04-09

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-01
• Study Completion Date: 2025-09-30

Brief Summary

Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.

There is preclinical and exploratory clinical evidence suggesting that ME-015 may be effective in treating cough caused by idiopathic pulmonary fibrosis (IPF cough).

80% of patients with idiopathic pulmonary fibrosis (IPF) are affected by a devastating dry cough that is often not responsive to standard cough treatments and causes significant psychological and physiological suffering as well as reduced quality of life. As of November 2024, there is no approved treatment for IPF cough. There is an enormous unmet clinical need for an effective, safe and well-tolerated oral treatment; particularly as approved antifibrotic treatments (pirfenidone and nintedanib) have not been shown to reduce cough in controlled clinical trials.

The COSMIC-IPF Phase 2a trial is the first clinical trial assessing ME-015 (an NCE outside of Japan) for the treatment of IPF cough and aims to generate clinical proof-of-concept results regarding the safety and efficacy of ME-015 in this condition.

Detailed Description

This quadruple blinded, cross-over, placebo-controlled clinical trial will randomize patients with stable idiopathic pulmonary fibrosis (IPF) and cough related to IPF (IPF cough) in a 1:1 fashion to one of two treatment sequences: active treatment followed by placebo, or placebo followed by active treatment. Each 14-day active/placebo treatment phase is preceded by a wash out period. The treatment sequences are followed by an observational 7-day follow-up period without medication. All subjects in the trial receive standard-of-care antifibrotic treatment for IPF. There is a single-blinded placebo run-in period before randomization to create a stable baseline and adjust for the anticipated placebo effect at study entry.

Treatment assignment is blinded to patients, investigators, site personnel, data analysts and Sponsor. The active treatment is ME-015 (Suplatast Tosilate) 200 mg t.i.d. (three times per day) administered as oral capsules. The placebo treatment consists of identical capsules without the active component.

The primary efficacy endpoint is the effect on awake time cough frequency measured objectively with the VitaloJak device over a 24-hour period. VitaloJak recordings are analysed using a blinded, independent, central review and validation process.

The study is conducted as a single-country, multi-centre clinical trial in India with Melius Pharma AB as the Sponsor. External central adjudication of HRCT images by a UK-based KOL ensures guideline-based diagnoses of IPF. Treatment needs to follow international guideline-based standard of care for IPF, and all Indian sites have been chosen to reflect a similar standard of care as practiced in Europe and the U.S. Only literate patients are enrolled into the trial and all patient-facing material is made available in English and all common local languages.

Conditions

Idiopathic Pulmonary Fibrosis; Cough; IPF; Fibrotic Lung Disease; Chronic Cough; Coughing

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment Arm 1

2 weeks of blinded active treatment, followed by 2 weeks of blinded placebo treatment (wash-out), followed by 2 weeks of blinded placebo treatment, followed by 1 week of follow-up with neither active nor placebo treatment

Group Type: EXPERIMENTAL

ME-015 (Suplatast Tosilate)

Intervention Type: DRUG

Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

Identical placebo

Intervention Type: OTHER

Without active component

Treatment Arm 2

2 weeks of blinded placebo treatment, followed by 2 weeks of blinded placebo treatment (wash-out), followed by 2 weeks of blinded active treatment, followed by 1 week of follow-up with neither active nor placebo treatment

Group Type: EXPERIMENTAL

ME-015 (Suplatast Tosilate)

Intervention Type: DRUG

Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

Identical placebo

Intervention Type: OTHER

Without active component

Interventions

ME-015 (Suplatast Tosilate)

Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

Intervention Type: DRUG

Identical placebo

Without active component

Intervention Type: OTHER

Other Intervention Names

Suplatast; Suplatast Tosilate

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of IPF according to 2018 ATS/ERS/JRS/ALAT guidelines, confirmed by high-resolution computed tomography (HRCT) chest scan taken < 2 years ago

2. Age ≥ 18 years

3. Cough attributed to IPF unresponsive to standard anti-tussive treatment and present for > 8 weeks

4. Arithmetic mean of ≥ 10 coughs/hour during waking hours

5. Ability to read, comprehend, and complete the ICF and all questionnaires in the study without help

6. Cough severity score of ≥ 40 mm on a 0-to-100 mm Visual Analogue Scale (VAS)

7. Willing and able to comply with the protocol

8. Life expectancy > 6 months

9. Stable medical condition: stable treatment for > 12 weeks and absence of acute exacerbations for > 4 weeks

10. FVC ≥ 40% predicted

11. FEV1 / FVC ≥ 65%

12. Women of childbearing potential must agree to use a highly effective method of contraception

13. Male partner must agree to use a condom during the study, unless they had a vasectomy > 6 months prior to first study drug administration

Exclusion Criteria

1. Likely need for lung transplantation in next 12 months

2. Permanent long-term oxygen therapy

3. Use of high-dose corticosteroids or cytotoxic medications

4. History of unstable or deteriorating cardiac or pulmonary disease in the preceding 6 months

5. Current smoking, vaping, or tobacco chewing

6. Treatment with an ACE inhibitor or sitagliptin

7. Any antitussive treatment, including opioid-based and OTC, for treatment of cough within 4 weeks of Screening or at any point during the study

8. BMI < 18 kg/m2 or ≥ 40 kg/m2

9. Suspected acute infection, including COVID-19 or influenza or any upper respiratory tract infection

10. History of malignancy within the last 2 years

11. History of drug/ alcohol dependency/ abuse within the last 2 years

12. Condition that could affect drug absorption

13. Recent history of stroke or TIA

14. Resting blood pressure > 160/90 mmHg

15. Pregnant/lactating women

16. Investigational drug or biologic within the last 2 months

17. Blood donation within the last 56 days or plasma donation within the last 7 days

18. Severe medical/ psychiatric condition posing risk to trial participation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Melius Pharma AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Aditya Multi Specialty Hospital

Guntur, Andhra Pradesh, India

KLE's Dr Prabhakar Kore Hospital & Medical Research Centre

Belagavi, Karnataka, India

ACE Hospital and Research Centre

Pune, Maharashtra, India

Hindusthan Hospital

Coimbatore, Tamil Nadu, India

GSVM Medical College, Murari Lal Chest Hospital

Kanpur, Uttar Pradesh, India

Health Point Hospital

Kolkata, West Bengal, India

Countries

India

Related Links

https://www.meliuspharma.com/

Sponsor website

Other Identifiers

SYNCD-070-22

Identifier Type: OTHER

Identifier Source: secondary_id

COSMIC-IPF

Identifier Type: -

Identifier Source: org_study_id